An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

The intrinsically disordered proteins (IDPs) do not attain a stable secondary or tertiary structure and rapidly change their ...

Craft Capital Management LLC acted as underwriter for the Offering (the “Underwriter”). VCL Law LLP acted as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. securities ...

Hyperspectral imaging is a technology that detects slight differences in color to pinpoint the characteristics and conditions ...

The new policy rolled out by the NIH capped the indirect costs for all institutions at a fixed rate of 15%. In 2023, NIH ...

With more than three weeks left in the first quarter, the value of med-tech IPOs for 2025 already exceeds the funds raised ...

Renovations are underway to expand USF’s medical engineering lab space with advanced technology to support a growing number ...

Advanced Biomed Inc. (the “Company” or “Advanced Biomed”), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the pricing ...

The U.S. IPO market seems to be cooling off this week, with no major listing planned. This week, Advanced Biomed (ADVB) is ...